For instance, decitabine and 5-azacytidine, used as DNMT inhibitors, have been clinically used in the therapy of high-risk myelodysplastic syndrome; however, these agents exhibited extensive toxicity and may destroy the functional and structural patterns of normal cells and even cause canceration [41]. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.